{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:31:26Z","timestamp":1789507886172,"version":"build-2803163510"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"SI","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical Research Council and Scleroderma & Raynaud\u2019s UK","award":["MR\/V030108\/1"],"award-info":[{"award-number":["MR\/V030108\/1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>SSc-interstitial lung disease (ILD) is one of the leading causes of mortality in SSc. Data from randomized controlled trials (RCTs) support rituximab and tocilizumab monotherapy but there are limited data regarding their use for those who fail standard immunomodulatory therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>SSc patients treated with rituximab or tocilizumab were retrospectively identified in a single centre cohort. Linear mixed effect models were used to analyse before and after treatment lung function trajectory, and identify patient characteristics associated with treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 127 patients were included for analysis. Fifty-one of 94 (54.2%) and 13 of 33 (39.4%) of the rituximab and tocilizumab cohorts, respectively, were receiving concurrent MMF. Pre-treatment decline in absolute change % forced vital capacity (%FVC)\/year and % diffusion capacity for carbon monoxide (%DLCO)\/year, respectively, was similar in both cohorts (\u22123.2% and \u22124.0% rituximab, and \u22123.2% and \u22123.6% tocilizumab). Both treatments resulted in lung function stabilization (%FVC\/year and %DLCO\/year: 1.2% and +0.2% rituximab cohort, 1.0% and 1.0% tocilizumab cohort). Anti-topoisomerase antibody (ATA)-positive patients had a significant response on %FVC\/year to tocilizumab compared with ATA-negative patients. Gender had a significant impact on %FVC\/year response to rituximab, with males responding to a greater degree than females. Age, ILD extent and skin subset had no impact on treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Combination rituximab or tocilizumab with background immunosuppressive therapy is associated with stabilization in lung function trajectory among those who remain refractory to standard immunosuppressives. Specific patient characteristics have an impact on lung function response. Improved FVC response among ATA patients receiving tocilizumab validate data from RCTs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf006","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T15:19:51Z","timestamp":1735831191000},"page":"SI184-SI189","source":"Crossref","is-referenced-by-count":12,"title":["Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: a real-world cohort analysis"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6800-4230","authenticated-orcid":false,"given":"Nina R","family":"Goldman","sequence":"first","affiliation":[{"name":"Division of Medicine, Centre for Rheumatology, University College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5178-9038","authenticated-orcid":false,"given":"Svetlana I","family":"Nihtyanova","sequence":"additional","affiliation":[{"name":"Division of Medicine, Centre for Rheumatology, University College London , London,","place":["UK"]},{"name":"Clinical Research, Immunology, GSK , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3254-729X","authenticated-orcid":false,"given":"Claire F","family":"Beesley","sequence":"additional","affiliation":[{"name":"Division of Medicine, Centre for Rheumatology, University College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2108-6248","authenticated-orcid":false,"given":"Athol U","family":"Wells","sequence":"additional","affiliation":[{"name":"Interstitial Lung Disease Unit, Royal Brompton Hospital, Guy\u2019s and St Thomas\u2019 Hospital NHS Foundation Trust , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3975-8938","authenticated-orcid":false,"given":"Christopher P","family":"Denton","sequence":"additional","affiliation":[{"name":"Division of Medicine, Centre for Rheumatology, University College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1118-797X","authenticated-orcid":false,"given":"Elisabetta A","family":"Renzoni","sequence":"additional","affiliation":[{"name":"Interstitial Lung Disease Unit, Royal Brompton Hospital, Guy\u2019s and St Thomas\u2019 Hospital NHS Foundation Trust , London,","place":["UK"]},{"name":"Margaret Turner-Warwick Centre for Fibrosing Lung Disease, Imperial College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1561-784X","authenticated-orcid":false,"given":"Rizgar","family":"Mageed","sequence":"additional","affiliation":[{"name":"Centre for Translation Medicine and Therapeutics, Queen Mary University , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5474-0053","authenticated-orcid":false,"given":"Voon H","family":"Ong","sequence":"additional","affiliation":[{"name":"Division of Medicine, Centre for Rheumatology, University College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"2025121017315308700_keaf006-B1","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025121017315308700_keaf006-B2","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S2213-2600(19)30480-1","article-title":"Systemic sclerosis-associated interstitial lung disease","volume":"8","author":"Perelas","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025121017315308700_keaf006-B3","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"New Engl J Med"},{"key":"2025121017315308700_keaf006-B4","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2025121017315308700_keaf006-B5","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.3390\/cells11233912","article-title":"Hematopoietic cell transplantation for systemic sclerosis\u2014a review","volume":"11","author":"Levin","year":"2022","journal-title":"Cells"},{"key":"2025121017315308700_keaf006-B6","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2025121017315308700_keaf006-B7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2025121017315308700_keaf006-B8","doi-asserted-by":"crossref","first-page":"2202071","DOI":"10.1183\/13993003.02071-2022","article-title":"Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial","volume":"61","author":"Mankikian","year":"2023","journal-title":"European Respiratory Journal"},{"key":"2025121017315308700_keaf006-B9","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"The Lancet"},{"key":"2025121017315308700_keaf006-B10","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025121017315308700_keaf006-B11","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/rheumatology\/kead234","article-title":"Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort","volume":"63","author":"Ghuman","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025121017315308700_keaf006-B12","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"Classification criteria for systemic sclerosis: an ACR-EULAR collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025121017315308700_keaf006-B13","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/art.41153","article-title":"Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis","volume":"72","author":"Nihtyanova","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025121017315308700_keaf006-B14","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2025121017315308700_keaf006-B15","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1136\/rmdopen-2022-002477","article-title":"Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort","volume":"8","author":"Kuster","year":"2022","journal-title":"RMD Open"},{"key":"2025121017315308700_keaf006-B16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3899\/jrheum.210273","article-title":"Anti-interleukin 6 therapy effect for refractory joint and skin involvement in systemic sclerosis: a real-world, single-center experience","volume":"49","author":"Panopoulos","year":"2022","journal-title":"J Rheumatol"},{"key":"2025121017315308700_keaf006-B17","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/thorax-2023-220541","article-title":"Phenotyping by persistent inflammation in systemic sclerosis associated interstitial lung disease: a EUSTAR database analysis","volume":"78","author":"Guler","year":"2023","journal-title":"Thorax"},{"key":"2025121017315308700_keaf006-B18","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.1016\/S2665-9913(22)00193-X","article-title":"Articles Sex differences in clinical outcomes and biological profiles in systemic sclerosis-associated interstitial lung disease: a post-hoc analysis of two randomised controlled trials","volume":"4","author":"Volkmann","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2025121017315308700_keaf006-B19","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1002\/art.30438","article-title":"Predicting Treatment Outcomes and Responder Subsets in Scleroderma-Related Interstitial Lung Disease","volume":"63","author":"Roth","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2025121017315308700_keaf006-B20","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/art.41668","article-title":"Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"73","author":"Roofeh","year":"2021","journal-title":"Arthritis Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf006\/61327987\/keaf006.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf006\/61327987\/keaf006.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf006\/61327987\/keaf006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T22:32:01Z","timestamp":1765405921000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/SI\/SI184\/7942510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":20,"journal-issue":{"issue":"SI","published-online":{"date-parts":[[2025,1,3]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf006","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,1,3]]}}}